Epidermal Growth Factor Receptor Mutation Is Associated With Longer Local Control After Definitive Chemoradiotherapy in Patients With Stage III Nonsquamous Non–Small-Cell Lung CancerShigehiro Yagishita, Tomohide Tamura, Hiroshi Nokihara et al.|International Journal of Radiation Oncology*Biology*Physics|2014Cited by 63
Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancerShinji Nakamichi, Akihiko Gemma|Oncotarget|2018Cited by 42
A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non–Small-Cell Lung Cancer: TORG2241 (UBE-Q)Shinji Nakamichi, Hiroaki Okamoto, Kaoru Kubota et al.|Clinical Lung Cancer|2023Cited by 6
Impact of the presence of EGFR mutation on definitive chemoradiotherapy in patients with locally advanced non-small cell lung cancer: Pattern of relapses and survival analyses in 145 patients.Shigehiro Yagishita, Tomohide Tamura, Hidehito Horinouchi et al.|Journal of Clinical Oncology|2013Cited by 0